Search for non-nucleoside inhibitors of HIV-1 reverse transcriptase using chemical similarity, molecular docking, and MM-GB/SA scoring

被引:72
|
作者
Barreiro, Gabriela [1 ]
Guimaraes, Cristiano R. W. [1 ]
Tubert-Brohman, Ivan [1 ]
Lyons, Theresa M. [1 ]
Tirado-Rives, Julian [1 ]
Jorgensen, William L. [1 ]
机构
[1] Yale Univ, Dept Chem, New Haven, CT 06520 USA
关键词
D O I
10.1021/ci700271z
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A virtual screening protocol has been applied to seek non-nucleoside inhibitors of HIV-1 reverse transcriptase (NNRTIs) and its K103N mutant. First, a chemical similarity search on the Maybridge library was performed using known NNRTIs as reference structures. The top-ranked molecules obtained from this procedure plus 26 known NNRTIs were then docked into the binding sites of the wild-type reverse transcriptase (HIV-RT) and its K103N variant (K103N-RT) using Glide 3.5. The top-ranked 100 compounds from the docking for both proteins were post-scored with a procedure using molecular mechanics and continuum solvation (MM-GB/SA). The validity of the virtual screening protocol was supported by (i) testing of the MM-GB/SA procedure, (ii) agreement between predicted and crystallographic binding poses, (iii) recovery of known potent NNRTIs at the top of both rankings, and (iv) identification of top-scoring library compounds that are close in structure to recently reported NNRTI HTS hits. However, purchase and assaying of selected top-scoring compounds from the library failed to yield active anti-HIV agents. Nevertheless, the highest-ranked database compound, S 10087, was pursued as containing a potentially viable core. Subsequent synthesis and assaying of S10087 analogues proposed by further computational analysis yielded anti-HIV agents with EC50 values as low as 310 nM. Thus, with the aid of computational tools, it was possible to evolve a false positive into a true active.
引用
收藏
页码:2416 / 2428
页数:13
相关论文
共 50 条
  • [21] Rational Design of Potent Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase
    Chong, Pek
    Sebahar, Paul
    Youngman, Michael
    Garrido, Dulce
    Zhang, Huichang
    Stewart, Eugene L.
    Nolte, Robert T.
    Wang, Liping
    Ferris, Robert G.
    Edelstein, Mark
    Weaver, Kurt
    Mathis, Amanda
    Peat, Andrew
    JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (23) : 10601 - 10609
  • [22] The synthesis of several tritiated non-nucleoside, HIV-1 reverse transcriptase inhibitors
    Hamill, Terence G.
    Brenner, Nancy J.
    Eng, Wai-Si
    Burns, H. Donald
    Journal of Labelled Compounds and Radiopharmaceuticals, 1998, 41 (04): : 319 - 327
  • [23] Arylsulfone-based HIV-1 non-nucleoside reverse transcriptase inhibitors
    Famiglini, Valeria
    Coluccia, Antonio
    Brancale, Andrea
    Pelliccia, Sveva
    La Regina, Giuseppe
    Silvestri, Romano
    FUTURE MEDICINAL CHEMISTRY, 2013, 5 (18) : 2141 - 2156
  • [24] In silico screening of HIV-1 non-nucleoside reverse transcriptase and protease inhibitors
    Leitao, Andrei
    Andricopulo, Adriano D.
    Montanari, Carlos A.
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2008, 43 (07) : 1412 - 1422
  • [25] Non-nucleoside inhibitors of HIV-1 reverse transcriptase binding calculations.
    Zhou, ZG
    Madrid, M
    Madura, JD
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2001, 222 : U397 - U397
  • [26] PYRIDONE DIARYL ETHER NON-NUCLEOSIDE INHIBITORS OF HIV-1 REVERSE TRANSCRIPTASE
    Kennedy-Smith, Joshua
    Arora, Nidhi
    Billedeau, Roland
    Fretland, Jennifer
    Hang, Julie
    Heilek, Gabrielle
    Harris, Seth
    Hirschfeld, Donald
    Javanbakht, Hassan
    Li, Yu
    Liang, Weiling
    Roetz, Ralf
    Smith, Mark
    Su, Guoping
    Suh, Judy
    Sweeney, Zachary
    Villasenor, Armando
    Wu, Jeffrey
    Yasuda, Dennis
    Klumpp, Klaus
    DRUGS OF THE FUTURE, 2009, 34 : 150 - 150
  • [27] Next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors
    Boone, LR
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2006, 7 (02) : 128 - 135
  • [28] Discovery and optimization of pyridazinone non-nucleoside inhibitors of HIV-1 reverse transcriptase
    Sweeney, Zachary K.
    Dunn, James P.
    Li, Yu
    Heilek, Gabrielle
    Dunten, Pete
    Elworthy, Todd R.
    Han, Xiaochun
    Harris, Seth F.
    Hirschfeld, Donald R.
    Hogg, J. Heather
    Huber, Walter
    Kaiser, Ann C.
    Kertesz, Denis J.
    Kim, Woongki
    Mirzadegan, Taraneh
    Roepel, Michael G.
    Saito, Y. David
    Silva, Tania M. P. C.
    Swallow, Steven
    Tracy, Jahari L.
    Villasenor, Armando
    Vora, Harit
    Zhou, Amy S.
    Klumpp, Klaus
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (15) : 4352 - 4354
  • [29] Systematic Investigation of Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase (NNRTIs)
    Anton Beyer
    Luckhana Lawtrakul
    Supa Hannongbua
    Peter Wolschann
    Monatshefte für Chemie / Chemical Monthly, 2004, 135 : 1047 - 1059
  • [30] The role of non-nucleoside reverse transcriptase inhibitors in children with HIV-1 infection
    Maddocks S.
    Dwyer D.
    Paediatric Drugs, 2001, 3 (9): : 681 - 702